Cerus (NASDAQ:CERS) CFO Sells $211,723.04 in Stock

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 127,544 shares of Cerus stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $1.66, for a total transaction of $211,723.04. Following the sale, the chief financial officer owned 1,040,551 shares of the company’s stock, valued at $1,727,314.66. The trade was a 10.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kevin Dennis Green also recently made the following trade(s):

• On Thursday, March 5th, Kevin Dennis Green sold 55,225 shares of Cerus stock. The stock was sold at an average price of $2.06, for a total transaction of $113,763.50.
• On Friday, March 6th, Kevin Dennis Green sold 27,796 shares of Cerus stock. The stock was sold at an average price of $2.01, for a total transaction of $55,869.96.

Cerus Trading Up 6.5%

Shares of Cerus stock traded up $0.11 on Monday, hitting $1.80. 1,334,517 shares of the company traded hands, compared to its average volume of 2,144,514. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. The company has a market cap of $345.91 million, a PE ratio of -22.50 and a beta of 1.51. The stock’s 50 day moving average price is $2.29 and its 200-day moving average price is $1.87. Cerus Corporation has a 52 week low of $1.12 and a 52 week high of $2.96.

Cerus (NASDAQ:CERS) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.The business had revenue of $64.58 million during the quarter, compared to analysts’ expectations of $59.31 million. Equities research analysts predict that Cerus Corporation will post -0.08 EPS for the current year.

Institutional Trading of Cerus

Several hedge funds have recently modified their holdings of CERS. Cubist Systematic Strategies LLC boosted its holdings in shares of Cerus by 152.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 62,854 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Cerus by 291.6% during the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock worth $1,986,000 after acquiring an additional 1,064,133 shares in the last quarter. Millennium Management LLC lifted its position in Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock valued at $4,479,000 after acquiring an additional 344,395 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Cerus in the first quarter valued at approximately $32,000. Finally, Savant Capital LLC boosted its stake in Cerus by 339.6% in the second quarter. Savant Capital LLC now owns 94,812 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 73,244 shares in the last quarter. 78.37% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CERS. Wall Street Zen cut shares of Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Zacks Research downgraded shares of Cerus from a “hold” rating to a “strong sell” rating in a research note on Thursday. Finally, TD Cowen restated a “buy” rating on shares of Cerus in a report on Monday, January 12th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce”.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.